Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 3/20 | 0.48 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | RARG | P13631 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386600 | 0.86 | TAAR1 (0.56) | MAPT | |
| SCHEMBL1861423 | 0.82 | MAPT (0.50) | RARARARBRARGMAPTKDM4E | |
| SCHEMBL17407191 | 0.79 | ALDH1A1 (0.54) | MAPTKDM4EGAAHSD17B10POLB | |
| SCHEMBL11216126 | 0.78 | KDM4E (0.55) | MAPTKDM4EGAAHSD17B10POLB | |
| SCHEMBL29978999 | 0.76 | KDM4E (0.74) | MAPTKDM4EGAAHSD17B10POLB | |
| SCHEMBL12187437 | 0.76 | F2R (0.41) | RARARARBRARGKDM4E | |
| SCHEMBL11533929 | 0.75 | SLC9A1 (0.56) | MAPTKDM4EGAAHSD17B10POLB | |
| SCHEMBL1856361 | 0.75 | RARA (0.56) | RARARARBRARGMAPTKDM4E | |
| SCHEMBL27337609 | 0.74 | RARG (0.85) | RARARARBRARG | |
| SCHEMBL26482564 | 0.74 | KDM4E (0.54) | MAPTKDM4EGAAHSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680395-B1 | NOVEL LIGAND ACTIVATING RAR RECEPTORS USED IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2011-05-25 | — | — | EP | disclosed |
| US-7439396-B2 | Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-10-21 | — | — | US | disclosed |
| US-20070004726-A1 | Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-01-04 | — | — | US | disclosed |
| EP-1680395-A2 | NOVEL LIGAND ACTIVATING RECEPTORS RARS USED FOR HUMAN MEDICINE AND COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037772-A2 | NOVEL LIGAND ACTIVATING RECEPTORS RARS USED FOR HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004726-A1 | Pharmaceutical/cosmetic compositions comprising novel ligands that activate RAR receptors | RARA, RARG, RARB | RARA 1/4885RARB 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.